Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
A new European registry Assessment of Real lIfe cAre-Describing EuropeaN hEart failure management (ARIADNE) collected real-world data on the use and tolerability of sacubitril/valsartan in the treatment of outpatients with HF-rEF from across Europe.
All patients were followed up for 12 months to determine clinical outcomes of death or hospitalization, including emergency department visits. NYHA status and left ventricular ejection fraction (LVEF) were also assessed during the observation period. Clinical events such as myocardial infarction (MI), stroke, and cardiovascular (CV) and non-CV death.
The 9,069 patients were stratified according to their HF treatment as follows: patients receiving conventional HF treatment without sacubitril/valsartan (including an ACEI/ARB; non-S/V group); patients receiving sacubitril/valsartan (S/V group).
The mean age was 68.1 years, and 23.9% were women. The most frequent comorbidities were arterial hypertension, coronary heart disease and dyslipidemia.
At baseline, 84% of patients in the non-S/V group were on ACEI/ARB therapy. Overall, 79% of patients were taking β-blockers, and 54% were receiving mineralocorticoid receptor antagonists. About 8.0% of patients were receiving ivabradine, and 7.5% of patients were receiving digitalis.
After 12 months, the proportion of patients with NYHA class III or IV symptoms decreased from 32.1% to 25.2% in the non-S/V group, and from 44.6% to 24.0% in the S/V group.
Incidence rates of clinical events per 100 patient-years
SCAC 03/23 CAR 001 MPAD
In a real-world setting, sacubitril/valsartan was associated with a higher incidence of stroke and MI and symptoms improvement in patients with HF-rEF compared with conventional HF-rEF therapy. ESC Heart Failure (2022) DOI: 10.1002/ehf2.14014
It can also interest you
Keep up to date with our content
Subscribe to our newsletter so that you are always up to date with the news.